April 2nd 2025
The phase 3 ROSELLA trial results assessing relacorliant/nab-paclitaxel in patients with platinum-resistant ovarian cancer will support an upcoming NDA.
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
Exploring the Benefits and Risks of AI in Oncology
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma
View More
Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care
View More
Biomarkers in Diffuse Large B-Cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes
View More
Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Options and Emerging Approaches
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Burst CME™: How is the Newly Approved CAR T-Cell Therapy Impacting R/R B-Cell ALL Management?
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases
View More
Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma
View More
Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies
View More
Panel Advocates Listing Estrogen as ‘Known’ Carcinogen
February 1st 2001WASHINGTON-A scientific advisory panel has recommended that steroid estrogens be listed as "known" to cause human cancers. However, the group made no recommendation or suggestion that the commonly used drugs be restricted or eliminated.
Is There a Role for Intraperitoneal Chemotherapy in the Management of Ovarian Cancer?
January 1st 2001Phase I and II clinical trial data have demonstrated the safety, pharmacokinetic advantage, and potential for enhanced cytotoxicity associated with the intraperitoneal administration of antineoplastic agents in the
Is There a Role for Intraperitoneal Chemotherapy in the Management of Ovarian
January 1st 2001Phase I and II clinical trial data have demonstrated the safety, pharmacokinetic advantage, and potential for enhanced cytotoxicity associated with the intraperitoneal administration of antineoplastic agents in the
Is There a Role for Intraperitoneal Chemotherapy in the Management of Ovarian
January 1st 2001Phase I and II clinical trial data have demonstrated the safety, pharmacokinetic advantage, and potential for enhanced cytotoxicity associated with the intraperitoneal administration of antineoplastic agents in the
Pharmacology of Antineoplastic Agents in Older Cancer Patients
December 1st 2000The fastest growing segment of the US population is the group over the age of 65 years. In the next 30 years, this group will comprise over 20% of the population. Because 60% of all cancers occur in this age group, there will be an expected rise in the total cancer burden.
Maternal Diet May Affect Child’s Cancer Risk, Studies Show
November 1st 2000PHILADELPHIA-To date, epidemiologic studies looking for a link between adult diet and cancer risk have proved disappointing. But research focusing on in utero nutrition and preschool and adolescent diet may be more fruitful, suggests Karin Michels, ScD, an epidemiologist and assistant professor of obstetrics, gynecology, and reproductive biology at Harvard Medical School.
New Methods of Diagnosis and Treatment May Offer Longer Survival in Ovarian Cancer Cancer Patients
November 1st 2000WASHINGTON-New diagnostic tests and effective second-line chemotherapeutic agents may transform ovarian cancer from a certain killer into a chronic disease capable of being managed with medications that are easy to administer, provide good quality of life, and reliably quash recurrences of disease, said Patricia Goldman and Agustin Garcia, MD.
UFT/Leucovorin Plus Weekly Paclitaxel in the Treatment of Solid Tumors
The palliation of symptoms and improvement of quality of life are important aspects of therapy in patients with incurable metastatic cancer. This article describes the preliminary results of a phase I study of uracil and tegafur, an orally available fluorouracil (5-FU) derivative combined with oral leucovorin plus weekly intravenous paclitaxel.
Improving Minority Access to Genetic Counseling for Cancer Risk
October 1st 2000The Second Annual Robert H. Lurie Comprehensive Cancer Center Health Policy Symposium, held last year in Chicago, was entitled “Cancer, Reaching Medically Underserved Populations: Low Literacy and Culturally Specific Barriers.”This is the fourth in a series of reports on the conference presentations, prepared for ONI by researchers at Northwestern Medical School, that will put the discussions into a broader context. This month’s article reviews a presentation by Chanita Hughes, PhD, Georgetown University Medical Center, Lombardi Cancer Center, Washington, DC.
NCI Tests Feasibility of Large Study of Lung Cancer Screening
October 1st 2000BETHESDA, Md-The National Cancer Institute has launched a randomized, 3,000-person study to determine the feasibility of doing a larger scale trial to test whether spiral CT screening improves lung cancer survival. Six centers began recruiting volunteers in early September and hope to enroll 500 subjects each by the end of October.
Improving Minority Participation in Prevention Trials
September 1st 2000CHICAGO-Advances in cancer screening, prevention, and treatment have led to decreased cancer incidence and mortality. However, the benefits of new early detection measures and treatment options are not shared equally among ethnic minorities and the medically underserved, and disparities in cancer morbidity and mortality remain.
Dose Reductions and Delays: Limitations of Myelosuppressive Chemotherapy
September 1st 2000Thrombocytopenia occurs at various grades of severity in patients with nonmyeloid malignancies undergoing chemotherapy with myelosuppressive agents. Frequently, it is the major dose-limiting hematologic toxicity, especially in the treatment of potentially curable malignancies such as leukemia, lymphomas, and pediatric cancers.
Irinotecan-Containing Chemotherapy Regimens Active in Pancreatic Cancer and Ovarian Cancer
August 1st 2000NEW ORLEANS-Treatments combining irinotecan (Camptosar) with other drugs are active and well-tolerated in patients with advanced and metastatic pancreatic and ovarian cancer, according to two reports presented at the 36th annual meeting of the American Society of Clinical Oncology.
Shorter Administration of Paclitaxel Approved for Treating Advanced Ovarian Cancer
August 1st 2000The US Food and Drug Administration (FDA) has approved a novel, shorter administration regimen for Bristol-Myers Squibb’s paclitaxel (Taxol) injection for the treatment of advanced ovarian cancer. The FDA granted approval for this new
Taxol 3-Hour Infusion Approved for Advanced Ovarian Cancer
August 1st 2000PRINCETON, NJ-Bristol-Myers Squibb Company announced in a press release that the FDA has approved a novel, shorter administration regimen for Taxol (paclitaxel) injection for the treatment of advanced ovarian cancer. The new 3-hour regimen offers patients the advantage of administration in an outpatient setting.
Clinical Status of Laparoscopic Bowel Surgery for GI Malignancy
August 1st 2000Laparoscopic colorectal surgery is being utilized increasingly for benign diseases. Recent published series have proven that morbidity and mortality from laparoscopic procedures are superior to those seen after traditional open
Commentary (Piver): Management of Intestinal Obstruction in the Patient With Ovarian Cancer
August 1st 2000Drs. Randall and Rubin address three subjects important to all patients with advanced-stage epithelial ovarian cancer: (1) the incidence and annual mortality associated with the disease, (2) the use of intestinal surgery at the time of initial surgery, and (3) the use of surgery for intestinal obstruction in patients with recurrent (or progressive) ovarian cancer. I believe that progress in all three areas has been made, albeit slowly.